Incheon, S. Korea, Jan 6, 2025 – Samsung Biologics will participate in the 43rd J.P. Morgan Healthcare Conference in San Francisco between January 13-16, 2025.
Samsung Biologics’ CEO and President John Rim will present the company’s achievements and business strategies for the coming year during the main track presentation on January 14.
Samsung Biologics will also meet with investors and potential clients at the Biotech Showcase. The company will mark a new phase of growth at Bio Campus II this year with the completion of Plant 5, bringing up the total capacity to 784,000 liters by April this year. Samsung Biologics also continues to diversify its portfolio, providing end-to-end antibody-drug conjugate (ADC) services at its new dedicated facility.
Incheon, S. Korea, Jan 6, 2025 – Samsung Biologics will participate in the 43rd J.P. Morgan Healthcare Conference in San Francisco between January 13-16, 2025.
Samsung Biologics’ CEO and President John Rim will present the company’s achievements and business strategies for the coming year during the main track presentation on January 14.
Samsung Biologics will also meet with investors and potential clients at the Biotech Showcase. The company will mark a new phase of growth at Bio Campus II this year with the completion of Plant 5, bringing up the total capacity to 784,000 liters by April this year. Samsung Biologics also continues to diversify its portfolio, providing end-to-end antibody-drug conjugate (ADC) services at its new dedicated facility.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO
Share article